- Home
- KRC vs KNSA Comparison
KRC vs KNSA Comparison
Compare KRC & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | KNSA |
|---|---|---|
| Founded | 1947 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.9B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | KRC | KNSA |
|---|---|---|
| Price | $33.94 | $77.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | $40.14 | ★ $98.00 |
| AVG Volume (30 Days) | ★ 1.3M | 429.7K |
| Earning Date | 10-22-2026 | 10-27-2026 |
| Dividend Yield | ★ 6.49% | N/A |
| EPS Growth | 31.07 | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | ★ $1,112,667,000.00 | $677,564,000.00 |
| Revenue This Year | N/A | $46.66 |
| Revenue Next Year | $2.16 | $22.90 |
| P/E Ratio | ★ N/A | $282.33 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $27.36 | $35.53 |
| 52 Week High | $43.58 | $82.94 |
Technical Indicators
Market Signals| Indicator | KRC | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 40.58 | 52.93 |
| Support Level | $33.71 | $74.47 |
| Resistance Level | $34.36 | $81.42 |
| Average True Range (ATR) | 0.62 | 2.46 |
| MACD | 0.01 | -0.16 |
| Stochastic Oscillator | 54.51 | 62.54 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.